Capstone Therapeutics (CAPS) Competitors $1.62 0.00 (0.00%) As of 07/21/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock CAPS vs. TRVN, PTPI, BIOR, HEPA, BPTSY, VRPX, VIRX, NCNA, KRBP, and TFFPShould you be buying Capstone Therapeutics stock or one of its competitors? The main competitors of Capstone Therapeutics include Trevena (TRVN), Petros Pharmaceuticals (PTPI), Biora Therapeutics (BIOR), Hepion Pharmaceuticals (HEPA), Biophytis (BPTSY), Virpax Pharmaceuticals (VRPX), Viracta Therapeutics (VIRX), NuCana (NCNA), Kiromic BioPharma (KRBP), and TFF Pharmaceuticals (TFFP). These companies are all part of the "pharmaceutical products" industry. Capstone Therapeutics vs. Its Competitors Trevena Petros Pharmaceuticals Biora Therapeutics Hepion Pharmaceuticals Biophytis Virpax Pharmaceuticals Viracta Therapeutics NuCana Kiromic BioPharma TFF Pharmaceuticals Trevena (NASDAQ:TRVN) and Capstone Therapeutics (NASDAQ:CAPS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment. Does the media refer more to TRVN or CAPS? In the previous week, Trevena's average media sentiment score of 0.00 equaled Capstone Therapeutics'average media sentiment score. Company Overall Sentiment Trevena Neutral Capstone Therapeutics Neutral Do insiders & institutionals believe in TRVN or CAPS? 13.6% of Trevena shares are owned by institutional investors. Comparatively, 2.6% of Capstone Therapeutics shares are owned by institutional investors. 2.7% of Trevena shares are owned by company insiders. Comparatively, 42.8% of Capstone Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Do analysts rate TRVN or CAPS? Trevena presently has a consensus price target of $5.00, indicating a potential upside of 449.45%. Given Trevena's stronger consensus rating and higher probable upside, analysts plainly believe Trevena is more favorable than Capstone Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trevena 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Capstone Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is TRVN or CAPS more profitable? Company Net Margins Return on Equity Return on Assets TrevenaN/A N/A -119.55% Capstone Therapeutics N/A N/A N/A Which has more volatility & risk, TRVN or CAPS? Trevena has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500. Comparatively, Capstone Therapeutics has a beta of -0.82, suggesting that its stock price is 182% less volatile than the S&P 500. Which has better earnings and valuation, TRVN or CAPS? Capstone Therapeutics has higher revenue and earnings than Trevena. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTrevena$443K1.97-$40.29M-$47.04-0.02Capstone Therapeutics$44.88M0.01-$2.56MN/AN/A SummaryTrevena beats Capstone Therapeutics on 5 of the 9 factors compared between the two stocks. Get Capstone Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CAPS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CAPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CAPS vs. The Competition Export to ExcelMetricCapstone TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$260K$2.93B$5.53B$9.40BDividend YieldN/A2.48%4.00%4.04%P/E RatioN/A17.4326.9819.12Price / Sales0.01302.72445.0298.80Price / CashN/A40.8024.9928.17Price / Book-0.087.648.145.70Net Income-$2.56M-$55.16M$3.24B$257.84M7 Day Performance7.28%3.75%2.58%2.98%1 Month Performance-7.95%13.83%8.39%13.28%1 Year PerformanceN/A3.03%32.70%17.13% Capstone Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CAPSCapstone TherapeuticsN/A$1.62flatN/AN/A$260K$44.88M0.0038TRVNTrevena1.2419 of 5 stars$0.94-5.5%$5.00+434.6%-84.7%$897K$443K-0.0240Positive NewsGap DownPTPIPetros PharmaceuticalsN/A$0.03-2.7%N/A-99.7%$888K$5.11M-0.0120Gap DownBIORBiora Therapeutics1.84 of 5 stars$0.15+6.5%$23.00+15,664.2%-97.8%$660K$892K-0.01120Gap UpHEPAHepion Pharmaceuticals0.1628 of 5 stars$0.06-6.3%N/A-99.9%$656KN/A-0.0120BPTSYBiophytisN/A$1.33-8.3%N/AN/A$467KN/A0.0030Gap DownVRPXVirpax PharmaceuticalsN/A$0.35+7.2%$75.00+21,110.4%-99.2%$439KN/A0.007VIRXViracta Therapeutics2.6609 of 5 stars$0.01-18.5%$1.75+15,809.1%N/A$437KN/A-0.0120Gap DownNCNANuCana2.7814 of 5 stars$0.05-15.9%$25.00+49,700.8%-98.3%$360KN/A-0.0130News CoveragePositive NewsHigh Trading VolumeKRBPKiromic BioPharmaN/AN/AN/AN/A$330KN/A-0.0660Gap DownHigh Trading VolumeTFFPTFF PharmaceuticalsN/A$0.07flatN/AN/A$289K$730K-0.0119 Related Companies and Tools Related Companies TRVN Alternatives PTPI Alternatives BIOR Alternatives HEPA Alternatives BPTSY Alternatives VRPX Alternatives VIRX Alternatives NCNA Alternatives KRBP Alternatives TFFP Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CAPS) was last updated on 7/22/2025 by MarketBeat.com Staff From Our PartnersGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredThis Could Be the Most Profitable Season of Your LifeInstitutional money is pouring in. Bitcoin ETFs are live. Altcoin adoption is accelerating. This is the sam...Crypto Swap Profits | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | SponsoredTrump’s Endgame? (R.I.P. China)Tucked inside a Silicon Valley factory, a bold new tech is quietly emerging—one that could ignite a $12 trilli...Brownstone Research | SponsoredLeaked Gov’t Memo Reveals $100 Trillion DeadlineOnly Days Left to Claim Your Share of Trump's $100T Play Trump's economic blueprint is about to go live, an...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capstone Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Capstone Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CAPS Stock Alerts